Northwest Biotherapeutics Files 8-K: Other Events
Ticker: NWBO · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1072379
| Field | Detail |
|---|---|
| Company | Northwest Biotherapeutics Inc (NWBO) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, other-events
Related Tickers: NWBO
TL;DR
NWBO filed an 8-K for 'Other Events' - need to see what's up.
AI Summary
On October 23, 2025, Northwest Biotherapeutics, Inc. filed an 8-K report. The filing indicates an 'Other Events' item, suggesting a significant development not covered by other standard 8-K categories. Specific details regarding the nature of this event, any associated financial implications, or parties involved are not immediately detailed in the provided excerpt.
Why It Matters
This filing signals a material event for Northwest Biotherapeutics, Inc. that requires immediate disclosure to investors, potentially impacting the company's stock price and strategic direction.
Risk Assessment
Risk Level: medium — The filing of an 8-K for 'Other Events' suggests a material development that could be positive or negative, requiring further investigation.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- October 23, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 0-35737 (file_number) — Commission File Number
- 94-3306718 (irs_id) — IRS Employer Identification No.
- 4800 Montgomery Lane , Suite 800 Bethesda , Maryland 20814 (address) — Principal Executive Offices
- ( 240 ) 497-9024 (phone_number) — Registrant's telephone number
FAQ
What specific event is being reported under 'Other Events' in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the exact nature of the 'Other Events' being reported, only that it is the subject of the filing.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 23, 2025.
What is the principal executive office address for Northwest Biotherapeutics, Inc.?
The principal executive offices are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.
In which state was Northwest Biotherapeutics, Inc. incorporated?
Northwest Biotherapeutics, Inc. was incorporated in Delaware.
What is the Commission File Number for Northwest Biotherapeutics, Inc.?
The Commission File Number for Northwest Biotherapeutics, Inc. is 0-35737.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2025-10-24 12:28:38
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
Filing Documents
- tm2529420d1_8k.htm (8-K) — 22KB
- 0001104659-25-102049.txt ( ) — 180KB
- nwbo-20251023.xsd (EX-101.SCH) — 3KB
- nwbo-20251023_lab.xml (EX-101.LAB) — 33KB
- nwbo-20251023_pre.xml (EX-101.PRE) — 22KB
- tm2529420d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On October 23, 2025, the Company filed a new Form S-3 registration their effective date. The Company's existing shelf registration went effective on October 25, 2022. As such, that registration statement expires on October 25, 2025. In order to maintain an ongoing effective shelf registration, it was necessary for the Company to file a new registration statement before the expiration of the existing one. Accordingly, the Company filed the new shelf registration on October 23, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: October 24, 2025 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman